Security: Series D Preferred
Location: Louisville, CO
CEO: Ken Collins
CMO: Roger Echols
CCO: Pete Letendre
New Investors: Duquesne Capital Management, Healthcare Investment Partners, MDS Capital Corp., undisclosed investor
Existing Investors: HealthCare Ventures, TPG Ventures, Morgenthaler Ventures, Perseus-Soros BioPharmaceutical Fund, Sequel Venture Partners, Temasek Holdings Pte Ltd and Quintiles Transnational
Board of Directors: Chris Christoffersen, Ken Collins, Geoff Duyk, Chris Earl, Nebojsa Janjic, Gus Lawlor, Dan Mitchell

- Replidyne is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products.

- Aquilo worked with the company to secure multiple term sheets and increase the size of the transaction from $40 million due to demand.

- In 2006, Replidyne successfully completed its IPO with Merrill Lynch, Morgan Stanley, Cowen and Company, and Pacific Growth Equities as underwriters.